Enveric Biosciences (ENVB)
NASDAQ:ENVB
ENVB Stock Chart & Stats
$3.72
-$0.12(-23.95%)
At close: 4:00 PM EST
$3.72
-$0.12(-23.95%)
Day’s Range― - ―
52-Week Range$1.75 - $17.83
Previous CloseN/A
Volume362.16K
Average Volume (3M)781.31K
Market Cap
$3.71M
Enterprise Value-$3.51M
Total Cash (Recent Filing)$4.68M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.74
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.85
Shares Outstanding1,887,535
10 Day Avg. Volume899,153
30 Day Avg. Volume781,309
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap-0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit17.45
Enterprise Value/Ebitda0.41
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-315
Revenue Forecast (FY)$10.00M
Bulls Say, Bears Say
Bulls Say
Strengthening Patent PortfolioA newly issued U.S. patent broadens composition and method protection for novel therapeutic molecules. Durable patent coverage supports exclusivity, licensing and partnership discussions, and creates multi-year protection that underpins long-term commercial and strategic value.
Very Low Leverage / Minimal DebtMinimal debt reduces refinancing and interest-rate risk, preserving operating flexibility for a development-stage biotech. Low fixed obligations let management prioritize R&D and regulatory progress rather than servicing debt, a structurally favorable position while clinical programs advance.
Mechanistic Validation Of Lead Candidate (EB-003)Proprietary in-house BRET assays demonstrating biologically relevant pathway engagement provide mechanistic clarity for EB-003. That differentiation can reduce clinical risk, inform biomarker strategies, and strengthen scientific rationale for regulators and partners over the medium term.
Bears Say
No Revenue And Persistent Net LossesA multi-year absence of revenue means the business lacks commercial validation and must rely on financing to fund operations. Persistent net losses increase execution risk, lengthen the path to self-sufficiency, and make achievement of sustainable profitability contingent on successful clinical outcomes.
Consistent Negative Operating And Free Cash FlowOngoing negative operating and free cash flow indicates R&D expenses convert into real cash burn rather than non-cash charges. Even with some improvement versus prior years, sustained cash outflows require continual external funding and limit ability to scale programs without dilution.
Eroded Equity And Small Asset BaseSharp erosion of equity and a small asset base materially constrain financial flexibility and increase sensitivity to adverse outcomes. A weakened capital base reduces negotiating leverage for partnerships and elevates the probability of future dilutive financings if clinical timelines extend.
Enveric Biosciences News
ENVB FAQ
What was Enveric Biosciences’s price range in the past 12 months?
Enveric Biosciences lowest stock price was $1.75 and its highest was $17.83 in the past 12 months.
What is Enveric Biosciences’s market cap?
Enveric Biosciences’s market cap is $3.71M.
When is Enveric Biosciences’s upcoming earnings report date?
Enveric Biosciences’s upcoming earnings report date is May 19, 2026 which is in 36 days.
How were Enveric Biosciences’s earnings last quarter?
Enveric Biosciences released its earnings results on Mar 27, 2026. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of N/A by $0.85.
Is Enveric Biosciences overvalued?
According to Wall Street analysts Enveric Biosciences’s price is currently Overvalued.
Does Enveric Biosciences pay dividends?
Enveric Biosciences does not currently pay dividends.
What is Enveric Biosciences’s EPS estimate?
Enveric Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enveric Biosciences have?
Enveric Biosciences has 1,887,535 shares outstanding.
What happened to Enveric Biosciences’s price movement after its last earnings report?
Enveric Biosciences reported an EPS of $0.85 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.787%.
Which hedge fund is a major shareholder of Enveric Biosciences?
Currently, no hedge funds are holding shares in ENVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enveric Biosciences
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Indaptus Therapeutics
―
GT Biopharma
―
Artelo Biosciences
―
Ownership Overview
13.68% Insiders
0.17% Mutual Funds
1.22% Other Institutional Investors
83.71% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---